Episode Details

Bivalent new vaccine, Moderna press release

Uploaded 19-08-22

https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx


Omicron-containing bivalent COVID booster candidate, mRNA-1273.214

(original mRNA-1273 vaccine),

Superior neutralizing antibody response

in baseline seronegative participants.

increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels.

mRNA-1273.214 50 μg booster dose, well-tolerated in the 437 study participants

The safety and reactogenicity profile of the mRNA-1273.214 50 μg booster dose was similar to that of mRNA-1273 50 μg

BA.1

SARS-CoV-2 variants of concern and variants under investigation in England

Technical briefing 44

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1093275/covid-technical-briefing-44-22-july-2022.pdf

BA.2 3.4%

BA.4 17.2%

BA.5 78.7%

Other 0.7%

US variants

https://covid.cdc.gov/covid-data-tracker/#variant-proportions

BA.5 88.8%

BA.4 5.3%

BA.4.6 5.1%

BA.2.12.1 0.8%

BA.2 0%

BA.1s 0%

Delta 0%

Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793551

Population-based cohort study of 297 individuals in Ontario, Canada,

with myocarditis or pericarditis following COVID-19 vaccination,

found higher rates of myocarditis or pericarditis associated with receipt of mRNA-1273 compared with BNT162b2 as a second dose,

particularly among male individuals aged 18 to 24 years.

The results suggest that there may be product-specific differences in rates of myocarditis or pericarditis after receiving mRNA vaccines

First bivalent COVID-19 booster vaccine approved by UK medicines regulator

https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulator

Moderna bivalent approved for adult booster doses by MHRA

Spikevax bivalent Original/Omicron

25 micrograms targets the original virus strain

25 micrograms targets Omicron

Omicron (BA.1) and the original 2020 strain

(was also found to generate a good immune response against BA.4 and BA.5)

Safety monitoring

side effects observed were the same as those seen for the original Moderna booster dose,

and were typically mild and self-resolving,

and no serious safety concerns were identified.

Global covid deaths

https://www.worldometers.info/coronavirus/

6,466,947

Evidence cited by HMRA

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2822%2900320-6/fulltext

Based on official reported COVID-19 deaths,

we e